RE-CIRCUIT study-randomized evaluation of dabigatran etexilate compared to warfarin in pulmonary vein ablation: Assessment of an uninterrupted periprocedural anticoagulation strategy

American Journal of Cardiology

Volumn 115, Issue 1, 2015, Pages 154-155

  Calkins, Hugh ^a   Gerstenfeld, Edward P ^a   Schilling, Richard ^b   Verma, Atul ^a   Willems, Stephan ^a  

^a NONE   (Germany)

^b London Center   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ANTICOAGULANT THERAPY; CATHETER ABLATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS (TOPIC); NOTE; PULMONARY VEIN ISOLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; ISCHEMIC ATTACK, TRANSIENT; STROKE; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; STROKE; THROMBOEMBOLISM;

EID: 84915747517     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.10.002     Document Type: Letter

References (2)

1. A.A. Bin Abdulhak, A.R. Khan, and A.P. Wimmer Dabigatran in catheter ablation of atrial fibrillation: a call for a randomized control trial Am J Cardiol 113 2014 2087 2088
2. Boehringer Ingelheim, Available at: http://us.boehringer-ingelheim.com/news-events/press-releases/press-release-archive/2014/06-20-14-boehringer-ingelheim-re-circuit-trial-pradaxa-dabigatran-etexilate-mesylate-nvaf-patients-undergoing-ablation.html. Accessed on August 14, 2014.